CytomX

+$0.05 (+3.18%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.

CEO

Sean A. McCarthy

Employees

174

Headquarters

South San Francisco, California

Founded

2010

CTMX Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

815.97K

High today

$1.63

Low today

$1.52

Open price

$1.61

Volume

587.26K

52 Week high

$7.85

52 Week low

$1.51

CTMX News

BenzingaMay 26

CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings

CytomX Therapeutics, Inc. CTMX initiated enrolment by dosing first patient in a Phase 1 dose-escalation study of CX-904 for patients with advanced solid tumors.

Analyst ratings

Buy

100%

Hold

Sell

CTMX Earnings

-$0.50

-$0.33

-$0.17

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 4, After Hours

Why Robinhood?

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. View more

CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings

100%

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.